NextCell Pharma AB (FRA:65G) E10: €-0.08 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:65G NextCell Pharma AB FRA:65G
42 GF Score
Price €0.07
GF Value €0.06
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is NextCell Pharma AB E10?

NextCell Pharma AB FRA:65G -5.84% 42 E10 is €-0.08 as of Dec. 2025. GuruFocus rates FRA:65G with a GF Score™ of 42/100 and a GF Value™ of €0.06 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

NextCell Pharma AB's adjusted earnings per share data for the three months ended in Dec. 2025 was €-0.011. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.08 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-27), NextCell Pharma AB's current stock price is €0.0726. NextCell Pharma AB's E10 for the quarter that ended in Dec. 2025 was €-0.08. NextCell Pharma AB's Shiller PE Ratio of today is .


NextCell Pharma AB  (FRA:65G) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


NextCell Pharma AB E10 Related Terms


NextCell Pharma AB E10 Historical Data

* Premium members only.

The historical data trend for NextCell Pharma AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCell Pharma AB E10 Chart

NextCell Pharma AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NextCell Pharma AB Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Dec25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.08

FRA:65G vs VRTX, REGN, RVMD: E10 Comparison

For the Biotechnology subindustry, NextCell Pharma AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextCell Pharma AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where NextCell Pharma AB's Shiller PE Ratio falls into.


FRA:65G
42GF Score
NextCell Pharma AB FRA:65G
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NextCell Pharma AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NextCell Pharma AB's adjusted earnings per share data for the three months ended in Dec. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-0.011/133.3900*133.3900
=-0.011

Current CPI (Dec. 2025) = 133.3900.

NextCell Pharma AB Quarterly Data

per share eps CPI Adj_EPS
201508 0.000 99.829 0.000
201605 -0.048 100.914 -0.063
201608 -0.037 100.968 -0.049
201611 -0.037 101.517 -0.049
201702 -0.047 102.037 -0.061
201705 -0.050 102.679 -0.065
201708 -0.039 103.138 -0.050
201711 -0.025 103.413 -0.032
201802 -0.034 103.678 -0.044
201805 -0.023 104.632 -0.029
201808 -0.025 105.197 -0.032
201811 -0.033 105.443 -0.042
201902 -0.019 105.641 -0.024
201905 -0.025 106.895 -0.031
201908 -0.015 106.716 -0.019
201911 -0.013 107.345 -0.016
202002 -0.016 106.742 -0.020
202005 -0.031 106.882 -0.039
202008 -0.014 107.571 -0.017
202011 -0.018 107.549 -0.022
202102 -0.021 108.190 -0.026
202105 -0.015 108.838 -0.018
202108 -0.010 109.780 -0.012
202111 -0.015 111.069 -0.018
202202 -0.022 112.834 -0.026
202205 -0.020 116.746 -0.023
202208 -0.021 120.573 -0.023
202211 -0.019 123.803 -0.020
202302 -0.023 126.321 -0.024
202305 -0.028 128.034 -0.029
202308 -0.017 129.560 -0.018
202311 -0.024 130.958 -0.024
202402 -0.026 132.046 -0.026
202405 -0.022 132.818 -0.022
202408 -0.019 132.052 -0.019
202411 -0.009 133.000 -0.009
202502 -0.010 133.744 -0.010
202505 -0.013 133.064 -0.013
202508 -0.007 133.440 -0.007
202512 -0.011 133.390 -0.011

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.08 mean?
NextCell Pharma AB (FRA:65G) has a E10 of €-0.08 as of Dec. 2025. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on NextCell Pharma AB and its competitors.
Is NextCell Pharma AB's E10 too high?
NextCell Pharma AB's current E10 is €-0.08. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's E10 compare to VRTX and REGN?
NextCell Pharma AB's E10 of €-0.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on NextCell Pharma AB and its competitors. NextCell Pharma AB's current E10 is €-0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (FRA:65G) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.06, compared to a current price of €0.07 — trading 21% above its estimated fair value. The current E10 is €-0.08. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For NextCell Pharma AB (FRA:65G), the current E10 is €-0.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NextCell Pharma AB (FRA:65G) Overvalued in 2026?

Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued. The current stock price of €0.07 is trading 21% above its estimated GF Value™ of €0.06. GuruFocus considers NextCell Pharma AB to be Modestly Overvalued.

Key valuation signals for FRA:65G:

  • E10: €-0.08
  • GF Value™: €0.06 vs. price of €0.07 (21% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the FRA:65G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NextCell Pharma AB Business Description

Other Exchanges NXTCL:Sweden
Address Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score

Get the complete analysis for FRA:65G

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.06
GF Value